Summary:
- The article discusses the U.S. FDA's (Food and Drug Administration) granting of the Regenerative Medicine Advanced Therapy (RMAT) designation to Grace Science's GS-100 gene therapy for the treatment of NGLY1 deficiency.
- NGLY1 deficiency is a rare genetic disorder that affects the body's ability to break down certain proteins, leading to various health problems.
- The RMAT designation is a special status that provides accelerated development and review for promising regenerative medicine therapies, which could help expedite the availability of this gene therapy for patients with NGLY1 deficiency.